Develop and commercialize Stapled Peptide medications.
.. Aileron, Roche to expand Stapled Peptide drug collaboration Aileron Therapeutics announced today that Roche will initiate a new system to expand its collaboration with Aileron to discover, develop and commercialize Stapled Peptide medications. The potential $1.1 billion drug development collaboration, launched in August 2010, encompassed up to five programs of strategic importance to Roche; initially Aileron released the collaboration around two key applications in oncology.All of this is very good news or bad news depending on your point of view. WHAT DO YOU THINK? Are you concerned that the abortion rate isn’t declining, content that protests are increasing, worried about new restrictions or other things. We want to hear from you. 25 Says with Most Abortions Crime Against Medical or Unborn Savior? Which 25 Says Had the Most?. 3SBio enters into exclusive license with DiNonA for advancement of Leukotuximab 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced it has entered into a special license with DiNonA Inc today. For the development, advertising and making of Leukotuximab, an anti JL-1 antibody for acute leukemia , including acute myelocytic leukemia and acute lymphoblastic leukemia , in the territory of Greater China and the Middle East .